DIY Life Web Search

Search results

1. Results From The WOW.Com Content Network

2. MVC COVID-19 vaccine - Wikipedia

   en.wikipedia.org/wiki/MVC_COVID-19_vaccine

   The MVC COVID-19 vaccine (Chinese: 高端新冠肺炎疫苗; pinyin: Gāoduān xīnguàn fèiyán yìmiáo; Wade–Giles: Kaotuan hsinkuan feiyen imiao), designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company ...

3. COVI-VAC (U.S. COVID-19 vaccine) - Wikipedia

   en.wikipedia.org/wiki/COVI-VAC_(U.S._COVID-19...

   Medical uses The vaccine is administered intranasally and requires a single dose. Pharmacology COVI-VAC is a live attenuated vaccine. Clinical trials Phase I In December 2020, Codagenix started a Phase I trial in the United Kingdom. In September 2021, Codagenix reported that the trial had shown COVI-VAC to be safe and immunogenic. References ^ "Serum Institute starts manufacturing Codagenix's ...

4. Sanofi–GSK COVID-19 vaccine - Wikipedia

   en.wikipedia.org/wiki/Sanofi–GSK_COVID-19_vaccine

   In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States. [12] On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants, [13] [14] [15] which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico, [16] Nigeria ...

5. Corbevax - Wikipedia

   en.wikipedia.org/wiki/Corbevax

   The phase II concluded in April 2021. In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study.

6. Valneva COVID-19 vaccine - Wikipedia

   en.wikipedia.org/wiki/Valneva_COVID-19_vaccine

   In April 2021, Valneva COVID-19 vaccine commenced phase III trials with approximately 4,000 participants. In August 2021, New Zealand was chosen for trialing on 300 adult volunteers, due to low case numbers and slow vaccine rollout. Positive results for the phase III trials were reported in October 2021. Society and culture

7. COVAX-19 - Wikipedia

   en.wikipedia.org/wiki/COVAX-19

   Medical uses It requires two doses 21 days apart given by intramuscular injection. Pharmacology COVAX-19 is a recombinant protein subunit. History Vaxine began work on a COVID-19 vaccine in January 2020. After developing a vaccine adjuvant the company decided to focus on a "recombinant protein-based vaccine". A phase 1 human trial started in June 2020. The phase 1 trial involved 40 ...